Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/1999

01-12-1999 | Paper Report

Brca1 and homologous recombination

Author: David Bertwistle

Published in: Breast Cancer Research | Issue 1/1999

Login to get access

Excerpt

Mouse and human cells mutant for BRCA1 or BRCA2 are sensitive to DNA-damaging agents, implicating these genes in the response to DNA damage. Mammalian cells have two major pathways for the repair of DNA double-strand breaks (DSBs), homologous recombination and non-homologous end joining (NHEJ). The BRCA1 and BRCA2 proteins colocalise with RAD51, the mammalian equivalent of the yeast Rad51 protein, which is involved in the repair of DNA DSBs by homologous recombination. This has led to the view that BRCA1 and BRCA2 might also be involved in the repair of DNA DSBs by homologous recombination. …
Literature
1.
Moynahan ME, Chiu JW, Koller BH, Jasin M: Brca1 controls homology-directed DNA repair. Mol Cell. 1999, 4: 511-518.CrossRefPubMed
Metadata
Title
Brca1 and homologous recombination
Author
David Bertwistle
Publication date
01-12-1999
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/1999
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-1999-66622

Other articles of this Issue 1/1999

Breast Cancer Research 1/1999 Go to the issue

Paper Report

17q aberrations in breast cancer

Paper Report

Impact of mammographic screening in New South Wales

Paper Report

Adenoviral topoisomerase II αgene transfer increases sensitivity of resistant cancer cells

Paper Report

Report from 16 year UK breast screening trial

Paper Report

Diet and survival following a diagnosis of breast cancer

Paper Report

Edinburgh breast screening trial, 14 year follow up
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits